Retinal Angiomatous Proliferation and Intravitreal Bevacizumab Injection by Kang, Jae Hoon et al.
Korean Journal of Ophthalmology 21(4):213-215, 2007
DOI : 10.3341/kjo.2007.21.4.213
213
Received: May 15, 2007    Accepted: October 8, 2007
Reprint requests to Se Woong Kang, MD. Department of Ophthal- 
mology, Samsung Medical Center, College of Medicine, Sungkyunkwan 
University, 50 Ilwon-dong, Gangnam-gu, Seoul, 135-230, Korea. Tel: 
82-2-3410-3562, Fax: 82-2-3410-0074, E-mail: swkang@smc.samsung.co.kr
Retinal Angiomatous Proliferation and Intravitreal 
Bevacizumab Injection
Jae Hoon Kang, MD, Kyung Ah Park, MD, Song Ee Chung, MD, Se Woong Kang, MD.
Department of Ophthalmology, Samsung Medical Center, College of Medicine, Sungkyunkwan University, Seoul, Korea
Purpose:  To evaluate the short-term efficacy and safety of intravitreal bevacizumab injection (IVBI) in 
patients with retinal angiomatous proliferation (RAP).
Methods: Seven eyes of 5 patients with RAP were included in this study. All of the eyes evidenced stage 
2 RAP lesions, except for one eye with a stage 3 lesion. IVBI (1.25 mg/0.05 cc) were conducted at 4 or 
6-week intervals. Complete ocular examinations, angiographic results and optical coherence tomographic 
findings before and after the IVBI were analyzed at baseline and upon the follow-up visits.
Results: Seven eyes were studied in 5 patients who had undergone IVBI. Partial (3 eyes) or complete (4 
eyes) regression of RAP was noted after IVBI in all of the studied eyes. Visual acuity improved in 5 of the 
eyes, and was stable in 2 of the eyes. One eye evidenced severe intraocular inflammation after IVBI and 
a subsequent development of new RAP, which was controlled with vitrectomy and repeat IVBI. 
Conclusions: This treatment was effective over 6 months, stabilizing or improving visual acuity and reducing 
angiographic leakage. These short-term results suggest that IVBI may constitute a promising therapeutic 
option, particularly in the early stages of RAP.
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Retinal angiomatous proliferation (RAP) is a distinct 
form of neovascular age-related macular degeneration, 
originating from the retinal vasculature.
1-4 Although laser 
photocoagulation, the surgical ablation of feeding retinal 
arterioles and draining venules, photodynamic therapy, and 
transpupillary thermotherapy have previously been reported 
as therapeutic modalities for RAP,
5-10 no effective treatment 
for RAP has yet been developed. It was reported in an 
experimental mouse study that excessive vascular endothelial 
growth factor expression may trigger the growth of new 
vessels toward the subretinal space from the deep retinal 
capillary plexus, and the new vessels were shown to enlarge 
and form a complex with other vessels.
11-13 This occurs in a 
fashion similar to the evolution of RAP, and suggests the 
possibility that anti-vascular endothelial growth factor may be 
utilized as a treatment for RAP. However, to the best of our 
knowledge, no previous reports regarding this issue have yet 
been filed in Korea. We hereby describe the short-term 
effectiveness and safety profile of intravitreal bevacizumab, 
a full-length recombinant monoclonal antibody for vascular 
endothelial growth factor A, delivered via injection (IVBI) 
into patients with RAP.
Materials and Methods
Seven consecutive eyes of five patients who had 
undergone IVBI for the treatment of RAP were included in 
this series. The study group was comprised of one man and 
four women. The mean age in the study group was 71.2 
years. The diagnosis of RAP was predicated on the 
results of fluorescein angiography and indocyanine green 
angiography. Six eyes were verified to have stage 2 RAP 
lesions, in accordance with the classifications established by 
Yannuzzi et al.
1 The remaining eye was confirmed to have 
a stage 3 RAP lesion. Four eyes with RAP were subjected 
to IVBI as an initial treatment. Three eyes with RAP which 
had recurred after surgical ablation were also included in this 
study. Both eyes were involved in all five patients, but IVBI 
was not considered to be an appropriate treatment modality 
in the fellow eyes of 3 subjects with RPE tears after 
photodynamic therapy or disciform scarring. Measurements 
of best-corrected visual acuity, slit lamp examinations, 
fluorescein angiography, indocyanine green angiography, and 
optical coherence tomography were conducted in all patients. 
The median pretreatment visual acuity was 20/100 (Table 1).
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Sex Age
(yrs) RAP stage Previous
treatment
Number of 
IVBI
VA
F/U (mo) Cx
Pre-injection Post-injection
1F 7 5
2 - 4 20/100 20/50 6 -
2 +
* 5 20/200 20/200 8 -
2F 8 1
2 - 4 20/100 20/50 6 -
2 - 4 20/250 20/66 6 -
3M 6 4 2 +
* 7 20/25 20/20 11 -
4F 7 1 3 +
* 8 20/32 20/32 12 -
5 F 65 2 - 7 20/160 20/100 10 +
†
RAP=retinal angiomatous proliferation, IVBI=intravitreal bevacizumab injection, VA=visual acuity, 
F/U=follow-up duration from the first IVBI, Cx=complication, 
*=surgical ablation and/or photodynamic therapy, 
†=severe intraocular inflammation and recurrence.
Table 1. Clinical characteristics of the study eyes
Fig. 1. Early and late phase indocyanine green angiogram (ICGA) of the right eye of the patient #2 shows focal
area of hyperfluorescence and discrete rim of hypofluorescence due to retinal pigment epithelial detachment 
before treatment (A, B). At 5 months after intravitreal bevacizumab injection (C, D) it shows partial ablation of
lesion on ICGA.
ml was injected into the superior pars plana area, 3.5 mm 
apart from the corneal limbus, using a 30-gauge needle, and 
the location of injection was then changed in the following 
sequence: 10 o'clock, 12 o'clock, and 2 o'clock, in order to 
avoid repeated injections at the same location. IVBI was 
initially conducted at 4 weeks and then afterward at 6-week 
intervals. Slit lamp examination, funduscopy, and optical 
coherence tomography were conducted on the same day of, 
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but prior to, the consequent IVBI. Fluorescein angiography 
and indocyanine green angiography were conducted at the 
discretion of the treating physician, and these tests were 
employed in order to determine the quantity of leakage and 
regression of the RAP lesion. Bevacizumab was injected up 
to 8 times. The mean follow-up duration after the initial IVBI 
was 8.4 months (range 6~12 months).
Results
On angiographic examinations conducted 5.6 months 
(range 4~7 months) after IVBI, partial (3 eyes) or complete 
(4 eyes) regressions of RAP and significant reductions of the 
hyperfluorescent lesions were noted in all of the study eyes. 
On the optical coherence tomographic examinations, a 
reduction in the central macular thickness, as well as a 
complete resolution of subretinal fluid and/or retinal pigment 
epithelial detachment were noted in all of the eyes on the 
final visit. Five eyes evidenced better visual acuity and 2 
eyes evidenced stable visual acuity. Median BCVA at the last 
visit had improved to 20/50. The visual results of the 
individual eyes are provided in Table 1.
In one case (patient #5 in Table 1) the patient was 
subjected to vitrectomy as the consequence of severe 
intraocular inflammation detected two days after the fourth 
IVBI. The bacterial culture of the vitreous specimen revealed 
no growth. The intraocular inflammation subsided as the 
result of intravitreal antibiotics and topical and systemic 
steroid treatments. Two weeks after the vitrectomy, the 
angiogram indicated a new RAP lesion. However, the RAP 
lesion regressed with repeated IVBI. Otherwise, no 
injection-related complications were detected.
Discussion
In all cases, stable or improved vision, reductions of 
central thickness on optical coherence tomography, and 
partial or complete obliterations of RAP on angiography were 
noted (Fig. 1). Our results indirectly bolster the notion that 
vascular endothelial growth factor contributes to the 
development of RAP. As the majority of our cases evidenced 
stage 2 RAP with pigment epithelial detachment, IVBI 
appears to work, at least in lesions of up to stage 2. As was 
noted in three eyes in this study, the recurrence or 
progression of RAP lesions after photodynamic therapy or 
surgical ablation are not infrequent occurrences. However, 
the development of such occurrences appears to be reduced 
as a consequence of IVBI. 
Although the number of cases in this study was rather 
small and the observation time was limited, IVBI appears 
initially to constitute an effective treatment, which can 
improve the prognosis of RAP. IVBI should be considered 
as a therapeutic option, particularly in cases in which RAP 
is diagnosed in an early stage.
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